124 related articles for article (PubMed ID: 29157747)
1. Multiplex Proximity Ligation Assay to Identify Potential Prognostic Biomarkers for Improved Survival in Locally Advanced Pancreatic Cancer Patients Treated With Stereotactic Body Radiation Therapy.
Rao AD; Liu Y; von Eyben R; Hsu CC; Hu C; Rosati LM; Parekh A; Ng K; Hacker-Prietz A; Zheng L; Pawlik TM; Laheru DA; Jaffee EM; Weiss MJ; Le DT; Hruban RH; De Jesus-Acosta A; Wolfgang CL; Narang AK; Chang DT; Koong AC; Herman JM
Int J Radiat Oncol Biol Phys; 2018 Feb; 100(2):486-489. PubMed ID: 29157747
[TBL] [Abstract][Full Text] [Related]
2. Outcomes for patients with locally advanced pancreatic adenocarcinoma treated with stereotactic body radiation therapy versus conventionally fractionated radiation.
Zhong J; Patel K; Switchenko J; Cassidy RJ; Hall WA; Gillespie T; Patel PR; Kooby D; Landry J
Cancer; 2017 Sep; 123(18):3486-3493. PubMed ID: 28493288
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of 18F-FDG PET /CT metabolic parameters in patients with locally advanced pancreatic Cancer treated with stereotactic body radiation therapy.
Ren S; Zhu X; Zhang A; Li D; Zuo C; Zhang H
Cancer Imaging; 2020 Mar; 20(1):22. PubMed ID: 32156306
[TBL] [Abstract][Full Text] [Related]
4. Albumin and Neutrophil-Lymphocyte Ratio (NLR) Predict Survival in Patients With Pancreatic Adenocarcinoma Treated With SBRT.
Alagappan M; Pollom EL; von Eyben R; Kozak MM; Aggarwal S; Poultsides GA; Koong AC; Chang DT
Am J Clin Oncol; 2018 Mar; 41(3):242-247. PubMed ID: 26757436
[TBL] [Abstract][Full Text] [Related]
5. Stereotactic body radiation therapy for locally advanced pancreatic cancer.
Jung J; Yoon SM; Park JH; Seo DW; Lee SS; Kim MH; Lee SK; Park DH; Song TJ; Ryoo BY; Chang HM; Kim KP; Yoo C; Jeong JH; Kim SC; Hwang DW; Lee JH; Song KB; Jo YY; Park J; Kim JH
PLoS One; 2019; 14(4):e0214970. PubMed ID: 30978229
[TBL] [Abstract][Full Text] [Related]
6. Quantitative Analysis of (18)F-Fluorodeoxyglucose Positron Emission Tomography Identifies Novel Prognostic Imaging Biomarkers in Locally Advanced Pancreatic Cancer Patients Treated With Stereotactic Body Radiation Therapy.
Cui Y; Song J; Pollom E; Alagappan M; Shirato H; Chang DT; Koong AC; Li R
Int J Radiat Oncol Biol Phys; 2016 Sep; 96(1):102-9. PubMed ID: 27511850
[TBL] [Abstract][Full Text] [Related]
7. Multiagent Chemotherapy and Stereotactic Body Radiation Therapy in Patients with Unresectable Pancreatic Adenocarcinoma: A Prospective Nonrandomized Controlled Trial.
Hill CS; Rosati L; Wang H; Tsai HL; He J; Hacker-Prietz A; Laheru DA; Zheng L; Sehgal S; Bernard V; Le DT; Pawlik TM; Weiss MJ; Narang AK; Herman JM
Pract Radiat Oncol; 2022; 12(6):511-523. PubMed ID: 35306231
[TBL] [Abstract][Full Text] [Related]
8. Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma.
Mellon EA; Hoffe SE; Springett GM; Frakes JM; Strom TJ; Hodul PJ; Malafa MP; Chuong MD; Shridhar R
Acta Oncol; 2015 Jul; 54(7):979-85. PubMed ID: 25734581
[TBL] [Abstract][Full Text] [Related]
9. Perioperative outcomes and survival following neoadjuvant stereotactic body radiation therapy (SBRT) versus intensity-modulated radiation therapy (IMRT) in pancreatic adenocarcinoma.
Chapman BC; Gleisner A; Rigg D; Meguid C; Goodman K; Brauer B; Gajdos C; Schulick RD; Edil BH; McCarter MD
J Surg Oncol; 2018 Apr; 117(5):1073-1083. PubMed ID: 29448308
[TBL] [Abstract][Full Text] [Related]
10. Higher Biologically Effective Dose Predicts Survival in SBRT of Pancreatic Cancer: A Multicentric Analysis (PAULA-1).
Arcelli A; Guido A; Buwenge M; Simoni N; Mazzarotto R; Macchia G; Deodato F; Cilla S; Bonomo P; Scotti V; Belgioia L; Tolento G; Cellini F; Grassi E; DI Marco M; Casadei R; Morganti AG; Cammelli S
Anticancer Res; 2020 Jan; 40(1):465-472. PubMed ID: 31892602
[TBL] [Abstract][Full Text] [Related]
11. The Role of Stereotactic Body Radiation Therapy for Pancreatic Cancer: A Single-Institution Experience.
Moningi S; Dholakia AS; Raman SP; Blackford A; Cameron JL; Le DT; De Jesus-Acosta AM; Hacker-Prietz A; Rosati LM; Assadi RK; Dipasquale S; Pawlik TM; Zheng L; Weiss MJ; Laheru DA; Wolfgang CL; Herman JM
Ann Surg Oncol; 2015 Jul; 22(7):2352-8. PubMed ID: 25564157
[TBL] [Abstract][Full Text] [Related]
12. Linac-based stereotactic body radiation therapy for unresectable locally advanced pancreatic cancer: risk-adapted dose prescription and image-guided delivery.
Mazzola R; Fersino S; Aiello D; Gregucci F; Tebano U; Corradini S; Di Paola G; Cirillo M; Tondulli L; Ruffo G; Ruggieri R; Alongi F
Strahlenther Onkol; 2018 Sep; 194(9):835-842. PubMed ID: 29696321
[TBL] [Abstract][Full Text] [Related]
13. Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated.
Chuong MD; Springett GM; Freilich JM; Park CK; Weber JM; Mellon EA; Hodul PJ; Malafa MP; Meredith KL; Hoffe SE; Shridhar R
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):516-22. PubMed ID: 23562768
[TBL] [Abstract][Full Text] [Related]
14. Individualized radiotherapy (iRT) concepts for locally advanced pancreatic cancer (LAPC): indications and prognostic factors.
Combs SE
Langenbecks Arch Surg; 2015 Oct; 400(7):749-56. PubMed ID: 26139242
[TBL] [Abstract][Full Text] [Related]
15. Role of stereotactic body radiation in the enhancement of the quality of life in locally advanced pancreatic adenocarcinoma: a systematic review.
Vornhülz M; Anton S; Eross B; Szakács Z; Hegyi P; Regel I; Belka C; Niyazi M; Mayerle J; Beyer G
Radiat Oncol; 2022 Jun; 17(1):108. PubMed ID: 35715808
[TBL] [Abstract][Full Text] [Related]
16. Change in carbohydrate antigen 19-9 level as a prognostic marker of overall survival in locally advanced pancreatic cancer treated with concurrent chemoradiotherapy.
Kim YJ; Koh HK; Chie EK; Oh DY; Bang YJ; Nam EM; Kim K
Int J Clin Oncol; 2017 Dec; 22(6):1069-1075. PubMed ID: 28477059
[TBL] [Abstract][Full Text] [Related]
17. Predictors and survival for pathologic tumor response grade in borderline resectable and locally advanced pancreatic cancer treated with induction chemotherapy and neoadjuvant stereotactic body radiotherapy.
Mellon EA; Jin WH; Frakes JM; Centeno BA; Strom TJ; Springett GM; Malafa MP; Shridhar R; Hodul PJ; Hoffe SE
Acta Oncol; 2017 Mar; 56(3):391-397. PubMed ID: 27885876
[TBL] [Abstract][Full Text] [Related]
18. Vertebral body and splenic irradiation are associated with lymphopenia in localized pancreatic cancer treated with stereotactic body radiation therapy.
Reddy AV; Deek MP; Jackson JF; Hill CS; Sehgal S; He J; Zheng L; Herman JM; Meyer J; Narang AK
Radiat Oncol; 2021 Dec; 16(1):242. PubMed ID: 34952610
[TBL] [Abstract][Full Text] [Related]
19. Stereotactic body radiation therapy boost in locally advanced pancreatic cancer.
Seo Y; Kim MS; Yoo S; Cho C; Yang K; Yoo H; Choi C; Lee D; Kim J; Kim MS; Kang H; Kim Y
Int J Radiat Oncol Biol Phys; 2009 Dec; 75(5):1456-61. PubMed ID: 19783379
[TBL] [Abstract][Full Text] [Related]
20. Prediction of overall survival after re-irradiation with stereotactic body radiation therapy for pancreatic cancer with a novel prognostic model (the SCAD score).
Zhu X; Li F; Ju X; Shen Y; Cao Y; Cao F; Fang F; Qing S; Jia Z; Zhang H
Radiother Oncol; 2018 Nov; 129(2):313-318. PubMed ID: 30217337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
